Willem P.T. Ruifrok

Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis

Lili Yu, Willem P.T. Ruifrok, Maxi Meissner et al. · Circulation Heart Failure · 2012 · 425 citations · Full text

Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial

Roberto Diletti, Wijnand K. den Dekker, Johan Bennett et al. · The Lancet · 2023 · 157 citations

Percutaneous Coronary Intervention, Cardiovascular Disease, Randomised Trial +9

Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: An open-label, blinded end point, randomized prospective trial (VitD-CHF trial)

Nicolas F. Schroten, Willem P.T. Ruifrok, Lennaert Kleijn et al. · American Heart Journal · 2013 · 121 citations

Blinded End Point, Hypertension, Heart Failure +8

The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload

Laura M.G. Meems, Megan V. Cannon, Hasan Mahmud et al. · The Journal of Steroid Biochemistry and Molecular Biology · 2012 · 73 citations

Diastolic Dysfunction, Hypertension, Medicine +5

Renal Handling of Galectin‐3 in the General Population, Chronic Heart Failure, and Hemodialysis

Wouter C. Meijers, A. Rogier van der Velde, Willem P.T. Ruifrok et al. · Journal of the American Heart Association · 2014 · 63 citations · Full text

Heart Failure, Renal Pathology, Renal Inflammation +22